These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 35609385)

  • 21. Future therapies for cystic fibrosis.
    Allen L; Allen L; Carr SB; Davies G; Downey D; Egan M; Forton JT; Gray R; Haworth C; Horsley A; Smyth AR; Southern KW; Davies JC
    Nat Commun; 2023 Feb; 14(1):693. PubMed ID: 36755044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    O'Carroll M
    Semin Respir Crit Care Med; 2023 Apr; 44(2):260-268. PubMed ID: 36893762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of CFTR modulators 2020.
    Goetz DM; Savant AP
    Pediatr Pulmonol; 2021 Dec; 56(12):3595-3606. PubMed ID: 34407318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
    Kotha K; Clancy JP
    Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation-specific therapies and drug repositioning in cystic fibrosis.
    Villella VR; Tosco A; Esposito S; Bona G; Raia V; Maiuri L
    Minerva Pediatr; 2019 Jun; 71(3):287-296. PubMed ID: 30761820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
    Egan ME
    Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis.
    Karb DB; Cummings LC
    Curr Gastroenterol Rep; 2021 Aug; 23(10):17. PubMed ID: 34448955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.
    McGarry ME; Gibb ER; Oates GR; Schechter MS
    Paediatr Respir Rev; 2022 Jun; 42():35-42. PubMed ID: 35277357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CFTR processing, trafficking and interactions.
    Amaral MD; Hutt DM; Tomati V; Botelho HM; Pedemonte N
    J Cyst Fibros; 2020 Mar; 19 Suppl 1():S33-S36. PubMed ID: 31680043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting ion channels in cystic fibrosis.
    Mall MA; Galietta LJ
    J Cyst Fibros; 2015 Sep; 14(5):561-70. PubMed ID: 26115565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning.
    Barry PJ; Ronan N; Plant BJ
    Semin Respir Crit Care Med; 2015 Apr; 36(2):287-98. PubMed ID: 25826594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies.
    Bresnick K; Arteaga-Solis E; Millar SJ; Laird G; LeCamus C
    BMJ Open Respir Res; 2021 Dec; 8(1):. PubMed ID: 34857524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.
    McGarry ME; McColley SA
    Pediatr Pulmonol; 2021 Jun; 56(6):1496-1503. PubMed ID: 33470563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cystic fibrosis - Ten promising therapeutic approaches in the current era of care.
    Somayaji R; Nichols DP; Bell SC
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1107-1124. PubMed ID: 32744089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.
    Fajac I; Sermet I
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis.
    Saluzzo F; Riberi L; Messore B; Loré NI; Esposito I; Bignamini E; De Rose V
    Cells; 2022 Apr; 11(7):. PubMed ID: 35406809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.
    Strub MD; McCray PB
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.